FRAMED Infrainguinal Venous Bypass Versus Conventional Autologous Bypass Trial
- Conditions
- Critical Limb-Threatening IschemiaPeripheral Arterial Occlusive DiseaseFemoropopliteal Artery OcclusionClaudication, IntermittentFemoropopliteal Stenosis
- Registration Number
- NCT06082466
- Lead Sponsor
- Paracelsus Medical University
- Brief Summary
The purpose of this clinical trial is to analyze patency after autologous infrainguinal bypass surgery in patients receiving a venous conduit versus a covered venous conduit.
- Detailed Description
Patients presenting to Vascular Surgical Units are usually multimorbid with increased cardiopulmonary risk. Autologous venous bypass is indicated in certain situations despite the longer duration of surgery. Optimizing patency has been an important goal since many years. Reconstruction problems are often based on intimal hyperplasia, which can be reduced via covering of the harvested vein as seen in previous studies.
This clinical trial will be conducted at our Division of Vascular Surgery and Endovascular Surgery at the University Hospital of Salzburg. Patients will be randomized into one of the two treatment options, which are a plain venous conduit or a by mesh covered venous conduit. During this clinical trial, the first follow-up will take place after 6 weeks; this corresponds to the usual follow-up interval. Due to the trial, further follow-ups will take place for each of the patients after 3 months, 6 months, 12 months, 2 years.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 110
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Incidence of primary patency of the venous bypass 2 years The incidence of patency of the venous bypasses will be analysed and compared. This is defined as freedom from occlusion of the venous bypass.
- Secondary Outcome Measures
Name Time Method Incidence of limb salvage after procedure 2 years Amputation free survival
Incidence of procedure-related mortality 2 years Mortality intervention-related
Incidence of 30-day mortality 30 days Number of participants, who die within 30 days after the procedure.
Trial Locations
- Locations (1)
University Hospital of Salzburg, Paracelsus Medical University
🇦🇹Salzburg, Austria
University Hospital of Salzburg, Paracelsus Medical University🇦🇹Salzburg, AustriaKlaus Linni, MD PDContactk.linni@salk.at